Design of clinical trials for therapeutic cancer vaccines development

European Journal of Pharmacology

Volumn 625, Issue 1-3, 2009, Pages 84-89

  Mackiewicz, Jacek ^a   Mackiewicz, Andrzej ^a,b  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b BioContract Sp Z Oo   (Poland)

Author keywords

Cancer vaccine; Clinical trial; Drug development; Efficacy trial; End point; Proof of principle trial; Whole cell cancer vaccine

Indexed keywords

AGI 101H; BIOLOGICAL MARKER; CANCER VACCINE; LACTATE DEHYDROGENASE; MELACINE; PROSTATE SPECIFIC ANTIGEN; PROVENGE; RENIALE; TUMOR CELL VACCINE; UNCLASSIFIED DRUG; VACCINE;

CANCER IMMUNOTHERAPY; CANCER STEM CELL; CANCER SURVIVAL; CLINICAL RESEARCH; CLINICAL TRIAL; COLORECTAL CANCER; DRUG EFFICACY; DRUG RESEARCH; DRUG RESPONSE; DRUG SYNTHESIS; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNE RESPONSE; KIDNEY CANCER; MELANOMA; MELANOMA CELL; METHODOLOGY; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; T LYMPHOCYTE; TREATMENT PLANNING;

ANIMALS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; GENE THERAPY; HUMANS; IMMUNOTHERAPY; NEOPLASMS; NEOPLASTIC STEM CELLS; PATIENT SELECTION;

EID: 71749109195     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.09.069     Document Type: Review

References (40)

1. Boman B.M., and Wicha M.S. Cancer stem cells: a step toward the cure. JCO 26 (2008) 2795-2799
2. Chapman P.B., Wu D., Ragupathi G., Lu S., Williams L., Hwu W.J., Johnson D., and Livingston P.O. Sequential immunization of melanoma patients with GD3 ganglioside vaccine and antiidiotypic monoclonal antibody that mimics GD3 ganglioside. Clin. Cancer. Res. 10 14 (2004) 4717-4723 15
3. Copier J., Ward S., and Dalgleish A. Cell based cancer vaccines: regulatory and commercial development. Vaccine 25S (2007) B35-B46
4. Copier J., Dalgleish A., Britten C.M., Finke L.H., Guadernack G., Gnjatic S., Kallen K., Kiesslilng R., Schuessler-Lenz M., Singh J., Talmadge J., Zwierzina J., and Hakansson L. Improving the efficacy of cancer immunotherapy. Eur. J. Cancer 45 (2009) 1424-1431
5. Fynan E.F., Webster R.G., Fuller D.H., Haynes J.R., Santoro J.C., and Robinson H.L. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc. Natl. Acad. Sci. U. S. A. 90 24 (1993) 11478-11482
6. Fisher M., Goldschmitt J., Peschel C., Brakenhoff J.P., Kallen K.J., Wollmer A., Grotzinger J., and Rose-John S. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat. Biotechnol. 15 (1997) 142-145
7. Goldman B., and DeFrancesco L. The cancer vaccine roller coaster. Nature Biotech. 27 2 (2009) 129-140
8. Hoos A., Parmiani G., Hege K., Sznol M., Loibner H., Eggermont A., Urba W., Blummenstain B., Sacks N., Keiholz U., and Nichol G. A clinical development paradigm for cancer vaccines and related biologics. J. Immunother. 30 (2007) 1-15
9. Iżycki D., Nawrocki S., Filas V., Gryska K., Lamperska K., Wiznerowicz M., Rose-John S., and Mackiewicz A. IL-6 and soluble IL-6 receptor gene modified tumor vaccine induces more effcient anti-melanoma immune responses and polarizes response towards Th1 type. Pol. J. Environ. Stud. 14 S2 (2005) 139-159
10. Jocham D., Richter A., Hoffmann L., Iwig K., Fahlenkamp D., Zakrzewski G., Schmitt E., Dannenberg T., Lechmacher W., von Wietersheim J., and Doehn C. Adjuvant autologous renal tumor cell vaccine and risk of tumor progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomized controlled trial. Lancet 363 (2004) 594-599
11. Kaufman H.L., Cohen S., Cheung K., DeRaffele G., Mitcham J., Moroziewicz D., Schlom J., and Hesdorffer C. Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors. Hum. Gene Ther. 17 2 (2006) 239-244
12. Leporowska, E. 2008. Selected laboratory indicators in monitoring of patients immunized with therapeutic gene modified melanoma vaccine. PhD. Thesis. Poznan, Poland 2008, 123 pp.
13. Mackiewicz, A. 2008. Vaccine composition. International Patent. PCT/EP/00780.
14. Mackiewicz A., Schooltink H., Heinrich P., and Rose-John S. Soluble human IL-6-receptor/IL-6 up-regulates expression of acute phase proteins. J. Immunol. 149 (1992) 2021-2027
15. Mackiewicz A., Gorny A., Laciak M., Malicki J., Murawa P., Nowak J., Wiznerowicz M., Hawley R.G., Heinrich P.C., and Rose-John S. Gene therapy of human melanoma. Immunization of patients with autologous tumor cells admixed with allogeneic melanoma cells secreting interleukin 6 and soluble interleukin 6 receptor. Hum. Gene Ther 6 (1995) 805-811
16. Mackiewicz A., Kapcinska M., Wiznerowicz M., Malicki J., Nawrocki S., Nowak J., Murawa P., Sibilska E., Kowalczyk D., Lange A., Hawley R.C., and Rose-John S. Immuno-gene therapy of human melanoma. Phase I/II trial. Adv. Exp. Med. Biol. 451 (1998) 557-560
17. Marshall J.A., Forster T.H., Purdie D.M., Lanagan C.M., O'Connor L.E., O'Rourke M.G., Johnson M.K., See J.L., Ellem K.A., Martinez N.R., López J.A., and Schmidt C.W. Immunological characteristics correlating with clinical response to immunotherapy in patients with advanced metastatic melanoma. Immunol. Cell Biol. 84 3 (2006) 295-302 Jun
18. Michaelis L.C., and Ratain M.J. Measuring response in a post-RECIST world: from black and white to shades of grey. Nat. Rev. Cancer 6 (2006) 409-414
19. Nawrocki S., and Mackiewicz A. Clinical trials of active cancer immunotherapy. Expert. Opin. Investig. Drugs. 16 (2007) 1137-1141
20. Nawrocki S., Murawa P., Malicki J., Kapcinska M., Gryska K., Lzycki D., Kaczmarek A., Laciak M., Czapczyk A., Karczewska A., Rose-John S., and Mackiewicz A. Genetically modified tumour vaccines (GMTV) in melanoma clinical trials. Immunol. Lett. 15 (2000) 81-86
21. Ozbek S., Peters M., Breuhahn K., Mann A., Blessing M., Fischer M., Schirmacher P., Mackiewicz A., and Rose-John S. The designer cytokine hyper-IL-6 mediates growth inhibition and GM-CSF-dependent rejection of B16 melanoma cells. Oncogene 20 (2001) 972-979
22. Pejwar-Gaddy S., and Finn O.J. Cancer vaccines: accomplishments and challenges. Crit. Rev. Oncol/Hematol. 67 (2008) 93-102
23. Pilla L., Patuzzo R., Rivoltini L., et al. A Phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complex Gp96, in combination with GM-SCF and interferon-alfa in metastatic melanoma patients. Cancer Immunol. Immunother. 55 8 (2006) 958-968
24. Rose-John S., Watzig G.H., Scheller J., Grotzinger J., and Seegert D. The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert. Opin. Ther. Targets 11 (2007) 613-624
25. Rosenberg S.A., Yang J.C., and Restifo N. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10 (2004) 909-915
26. Schatton T., and Frank M.H. Cancer stem cells and human malignant melanoma. Pigment Cell Melanoma Res. 21 (2007) 39-55
27. Schatton T., Murphy G.F., Frank N.H., Yamaura K., Waaga-Gasser A.M., Gasser M., Zhan O., Jordan S., Duncan L.M., Weishaupt C., Fuhibrigge R.C., Kupper T.S., Savegh M.H., and Frank M.H. Identification of cells initiating human melanoma. Nature 17 451 (2008) 345-349
28. Simon R.M., Steinberg S.M., Hamilton M., Hildesheim A., Khleif S., Kwak L.W., Mackall C.L., Schlom J., Topolian S.L., and Berzofsky J.A. Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J. Clin. Oncol. 19 (2001) 1848-1854
29. Small E.J., Schellhammer P.F., and Higano C.S. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24 (2006) 3089-3094
30. Sondak V.K., and Sosman J.A. Results of clinical trial with an allogeneic melanoma tumor cell lysate vaccine: Melacine. Semin. Cancer. Biol. 13 (2003) 409-415
31. Stebbing J., Eood Ch., Atkins M., Bukowski R., Litwin S., Bower M., Parsa A., and H. L. Cancer vaccines: clinical development challenges and proposed regulatory approaches for patient access to promising treatments. Cancer 112 (2008) 955-961
32. Uyl-de Groot C.A., Vermorken J.B., Hanna M.G., Verboom P., Groot M.T., Bonsel G.J., Meijer C.J., and Pinedo H.M. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. Vaccine 23 (2005) 2379-2387
33. Von Hoff D.D. There are no bad anticancer agents, only bad clinical trial designs - twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. Clin. Cancer Res. 4 (1998) 1079-1089
34. Wang F., Bade E., Kuniyoshi C., Spears L., Jeffery G., Marty V., Groshen S., and Weber J. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin. Cancer Res. 5 10 (1999) 2756-2765
35. Weber J., Sondak V.K., Scotland R., Phillip R., Wang F., Rubio V., Stuge T.B., Groshen S.G., Gee C., Jeffery G.G., Sian S., and Lee P.P. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected stage II melanoma. Cancer 97 1 (2003) 186-200 1
36. Weber J., Boswell W., Smith J., Hersh E., Snively J., Diaz M., Miles S., Liu X., Obrocea M., Qiu Z., and Bot A. Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma. J. Immunother. 31 2 (2008) 215-223
37. Wysocki, P.J., Kazimierczak, U., Suchorska, W., Kotlarski, M., Malicki, J., Mackiewicz, A., in press. Immunotherapy with irradiated RNECA cells modified with Hyper-IL-6 gene is highly effective treatment in therapeutic (palliative) and adjuvant setting in mice with orthotopic renal cell cancer. Cancer Gen Ther.
38. Zabierowski S.E., and Herlyn M. Melanoma stem cells: the dark seed of melanoma. JCO 28 17 (2008) 2890-2894
39. Guideline for Potency Testing of Cell-Based Immunotherapy Medicinal Products for Treatment of Cancer: EMEA/CHMP/410869/2006. Committee For Medicinal Products for Human Use, European Medicines Agency, London UK (2006). http://www.emea.europa.eu/pdfs/human/bwp/27147506en.pdf.
40. Regulation (EC) No 1394/2007 of the European Parliament and of The Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004. http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-1/reg_2007_1394/reg_2007_1394_en.pdf.